BARDA awards Ebola vaccine contract to NewLink Genetics
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:44AM CST
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)
NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
GlobeNewswire - Mon Dec 22, 7:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
NewLink Genetics: Examining Likelihood Of Success In The Impress Trial
Mind Craft - Seeking Alpha - Wed Dec 17, 11:50AM CST
Background The goal of immunotherapy, now recognized as the future direction of cancer treatment [1] , is to boost the immune response, and/or to remove whatever is limiting it, such that the balance shifts from tolerance to rejection. Tumors...
MRK: 57.46 (+0.25), INCY: 71.57 (+1.99), NLNK: 39.08 (+1.36), BMY: 59.15 (-0.01)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)
Gavi gives Ebola vaccine developers an extra incentive to move quickly
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 10:58AM CST
JNJ: 104.59 (+0.31), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 8:11AM CST
SPLS: 17.82 (-0.01), PBR: 7.60 (-0.11), RH: 96.97 (-0.16), PBR.A: 7.95 (-0.04), NLNK: 39.08 (+1.36), LAKE: 8.94 (+0.07), ODP: 8.75 (+0.06), NBG: 1.95 (+0.06)
Merck-NewLink Ebola vaccine trial interrupted
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 7:08AM CST
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)
Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST
NVAX: 5.81 (+0.18), NLNK: 39.08 (+1.36), OSUR: 10.26 (+0.25)
Biotech industry group supports adding Ebola to Voucher Program Act
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 12:57PM CST
JNJ: 104.59 (+0.31), BCRX: 11.83 (+0.76), CMRX: 36.80 (+0.70), HEB: 0.22 (-0.02), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11)
Hydration could save many Ebola victims
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:19AM CST
JNJ: 104.59 (+0.31), BCRX: 11.83 (+0.76), HEB: 0.22 (-0.02), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11), IXJ: 100.54 (+0.55), IRY: 47.28 (-0.01)
Phase 1 underway for Ebola booster vaccine regimen
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 7:23AM CST
JNJ: 104.59 (+0.31), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11)
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 6.99 (-0.03), VRTX: 115.15 (+1.40), NLNK: 39.08 (+1.36), IBIO: 0.68 (-0.04), CTIC: 2.36 (+0.05)
Ebola Stocks on the Rise as Death Toll Hits 5,000
ACCESSWIRE - Mon Dec 01, 11:28AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / The death toll from the current Ebola outbreak has nearly hit 5,000 according to the World Health Organization (WHO). While the spread seems to be thankfully slowing, the Ebola stock phenomenon has now transitioned from fear-based speculative buying to concrete capital flows. Lakeland Industries (NASDAQ:LAKE), after surging on the mere news of Ebola and speculation that this would increase demand for the company's hazmat suits, is now surging again on the news that, indeed, the suits are starting to sell. Lakeland last week announced total orders of over one million Ebola suits from both government agencies and private sector customers. Sales will be accretive to earnings after January 31, 2015.
APT: 2.55 (-0.03), NLNK: 39.08 (+1.36), LAKE: 8.94 (+0.07), GSK: 42.85 (+0.11)
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014
M2 - Mon Dec 01, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/22wv9l/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - Adamis - Aeterna Zentaris - Alethia Biotherapeutics - Amgen - AnGes MG - Antoxis - Aphios - Armour - Arno - Astellas Pharma - Astex - AstraZeneca - Ausio - Bavarian Nordic - Bayer - Beta Pharma - Bio-Cancer Treatment International - Biscayne - Boehringer Ingelheim - Celldex - CureTech - CytoVac A/S - DexTech Medical - Enceladus BV - Endo - EndoCeutics - Endocyte - Errant Gene - Fujifilm - Genentech - Glactone Pharma - GlaxoSmithKline - GTx - Harbor - Hybrigenics - Incuron - Io - Isis - Johnson & Johnson - Kinex - Medivation - Medvio Eurasia - Merck KGaA - Millennium - NewLink Genetics - Novartis AG - Oncogenex - Orion Oyj - Orphagen - Oxford BioMedica - Panacela Labs - Tokai - Viamet For more information visit http://www.researchandmarkets.com/research/22wv9l/hormone
JNJ: 104.59 (+0.31), NLNK: 39.08 (+1.36), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)
Dow 30 Stock Roundup: Merck Inks Ebola Deal, UTX CEO Retires - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Nov 28, 11:31AM CST
The Dow has had a largely positive holiday shortened week.
T: 33.96 (-0.07), ERIC: 12.30 (+0.07), IBM: 161.82 (-0.42), UTX: 116.91 (-0.30), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), WMT: 86.43 (-0.23), INTC: 37.44 (+0.01), VZ: 47.67 (unch)
Glaxo's Ebola Candidate Well-Tolerated in Early U.S. Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 10:49AM CST
GlaxoSmithKline's (GSK) Ebola vaccine candidate was well-tolerated in 20 adult volunteers in the U.S.
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), AMAG: 43.02 (+0.90), GSK: 42.85 (+0.11)
InsiderInsights.com Daily Round Up 11/25/14: AAPL, FCF, AVID, SC
InsiderInsights - at Seeking Alpha - Wed Nov 26, 12:20AM CST
SC: 20.09 (-0.19), ACMP: 56.75 (-0.56), NEOT: 6.65 (+0.25), BBY: 38.89 (-0.80), SGM: 12.35 (+0.05), FIVE: 38.76 (-0.11), AVID: 14.36 (+0.26), FCF: 9.21 (-0.04), SPW: 86.64 (-0.11), NLNK: 39.08 (+1.36), AINC: 89.50 (+2.50), PF: 35.32 (+0.13), AAPL: 112.01 (-0.53), SFXE: 4.42 (+0.04), INTU: 94.59 (-0.56), CSCO: 28.30 (+0.05), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 6.61 (+0.06), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11), SRNE: 9.50 (+0.99), NEPT: 1.88 (+0.03), CELG: 109.60 (+3.48)